{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-014944","form_type":"8-K","ticker":"INKT","cik":"0001840229","company_name":"MiNK Therapeutics, Inc.","filed_at":"2024-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.907144+00:00","generated_at":"2026-06-06T02:36:01.486466+00:00","sec_items":["1.01","2.03"],"event_type":"debt","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"MiNK Therapeutics issues up to $5.0M convertible promissory note to Agenus at 2% interest","bullets":["Principal amount up to $5.0M; interest rate 2% per annum, accruing but payable upon conversion or maturity.","Demand repayment on or after Jan 1, 2026; optional conversion into equity upon qualified financing at Agenus's election.","Funds may be drawn in increments with Agenus's consent; advances may include payments made by Agenus on Company's behalf."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-014944","json":"https://secwatch.observer/filing/0000950170-24-014944.json","markdown":"https://secwatch.observer/filing/0000950170-24-014944.md","text":"https://secwatch.observer/filing/0000950170-24-014944.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840229/000095017024014944/0000950170-24-014944-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840229/000095017024014944/inkt-20240212.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T02:36:01.486466+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"709a579e5af97908ab8ca0a2a71e95ee70454f63","claim":"MiNK Therapeutics, Inc. incurred convertible notes of up to $5.0 million with Agenus Inc. at 2% maturing on or after January 1, 2026.","evidence_excerpt":"On February 12, 2024, MiNK Therapeutics, Inc. (the “Company”) and Agenus Inc. (“Agenus”) entered into a Convertible Promissory Note Purchase Agreement (the “Purchase Agreement”) pursuant to which the Company issued to Agenus a Convertible Promissory Note in the principal amount of up to $5.0 million (the “Note”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840229/000095017024014944/0000950170-24-014944-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"up to $5.0 million"},{"label":"Counterparty","value":"Agenus Inc."},{"label":"Rate","value":"2%"},{"label":"Maturity","value":"on or after January 1, 2026"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"83c770e5af204db8c9dc679626e076e31b1237dd","claim":"MiNK Therapeutics, Inc. entered into Convertible Promissory Note Purchase Agreement with Agenus Inc. valued at $5.0 million (effective 2024-02-12).","evidence_excerpt":"On February 12, 2024, MiNK Therapeutics, Inc. (the “Company”) and Agenus Inc. (“Agenus”) entered into a Convertible Promissory Note Purchase Agreement (the “Purchase Agreement”) pursuant to which the Company issued to Agenus a Convertible Promissory Note in the principal amount of up to $5.0 million (the “Note”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840229/000095017024014944/0000950170-24-014944-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"Agenus Inc."},{"label":"Value","value":"$5.0 million"},{"label":"Effective","value":"2024-02-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}